Literature DB >> 16015440

Value of absence of a transient myocardial perfusion defect during stress myocardial perfusion study in patients undergoing major vascular surgery.

Jaafer A Golzar1, Assad Movahed.   

Abstract

Pre-operative cardiac assessment is important in the evaluation of patients undergoing major vascular surgery. Our study aims to evaluate the value of absence of a transient myocardial perfusion defect during radionuclide myocardial perfusion study for prediction of cardiac events (myocardial infarction, sudden cardiac death, unstable angina, coronary artery revascularization and congestive heart failure) in patients undergoing major vascular surgery. We studied 63 consecutive patients (ages 35-83 [avg. 64], male 39, female 24) with radiographically proven, abdominal aortic aneurysm or severe aortofemoral occlusive disease who underwent major vascular surgery (abdominal aortic aneurysm repair [38] or aortofemoral bypass [25]). The subjects all had multiple coronary artery risk factors (hypertension 48, diabetes 10, hyperlipidemia 23, tobacco use 39, family history of coronary artery disease 10), but a negative pre-operative stress myocardial perfusion study for myocardial ischemia. Of these 63 patients, 17 patients were able to exercise and achieve their adequate 85% maximal predicted heart rate. Thirty-eight patients received adenosine infusion of 140 microg/kg/min for 6 min. Six patients received dipyridamole infusion of 0.56 mg/kg over 4 min. Two patients received dobutamine infusion at 5, 10, 20, 30, and 40 mg/kg/min. Of the 63 patients, 60 received 3-4 mCi of thallium-201 ((201)Tl) and 3 patients received 8-9 mCi of technetium-99m (99mTc) at rest and 25-30 mCi 99mTc during stress. The subjects all underwent major vascular surgery and were followed up to one year for any cardiac events. Of the 63, who underwent pre-operative cardiac assessment with myocardial perfusion testing, 25 had a fixed myocardial perfusion defect (scar) and none had evidence of transient myocardial perfusion defect (ischemia). One subject had coronary artery bypass grafting 11 months after aortofemoral bypass surgery. One died from a stroke one month after aortofemoral bypass surgery. Of the remaining 61 patients, none had any cardiac events up to one year after major vascular surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015440     DOI: 10.1007/s10554-004-6132-1

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  18 in total

Review 1.  The question: to test or not to test in preoperative cardiac risk evaluation.

Authors:  J A Leppo; S T Dahlberg
Journal:  J Nucl Cardiol       Date:  1998 May-Jun       Impact factor: 5.952

2.  Cardiac assessment prior to vascular surgery: is dipyridamole-sestamibi necessary?

Authors:  C de Virgilio; S Pak; T Arnell; C Donayre; R J Lewis; B E Stabile; R White
Journal:  Ann Vasc Surg       Date:  1996-07       Impact factor: 1.466

3.  Perioperative and long-term prognostic value of intravenous dipyridamole thallium scintigraphy in patients with peripheral vascular disease.

Authors:  L T Younis; F Aguirre; S Byers; S Dowell; G Barth; H Walker; B Carrachi; G Peterson; B R Chaitman
Journal:  Am Heart J       Date:  1990-06       Impact factor: 4.749

4.  Dipyridamole-thallium scintigraphy and gated radionuclide angiography to assess cardiac risk before abdominal aortic surgery.

Authors:  J F Baron; O Mundler; M Bertrand; E Vicaut; E Barré; G Godet; C M Samama; P Coriat; E Kieffer; P Viars
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

5.  Dipyridamole thallium imaging may not be a reliable screening test for coronary artery disease in patients undergoing vascular surgery.

Authors:  T H Marwick; D A Underwood
Journal:  Clin Cardiol       Date:  1990-01       Impact factor: 2.882

6.  Determination of cardiac risk by dipyridamole-thallium imaging before peripheral vascular surgery.

Authors:  C A Boucher; D C Brewster; R C Darling; R D Okada; H W Strauss; G M Pohost
Journal:  N Engl J Med       Date:  1985-02-14       Impact factor: 91.245

7.  Asymptomatic myocardial ischemia during percutaneous transluminal coronary angioplasty and importance of prior Q-wave infarction and diabetes mellitus.

Authors:  B G Titus; C T Sherman
Journal:  Am J Cardiol       Date:  1991-09-15       Impact factor: 2.778

8.  Dipyridamole thallium-201 scintigraphy as a preoperative screening test. A reexamination of its predictive potential. Study of Perioperative Ischemia Research Group.

Authors:  D T Mangano; M J London; J F Tubau; W S Browner; M Hollenberg; W Krupski; E L Layug; B Massie
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

9.  Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery.

Authors:  L J Shaw; K A Eagle; B J Gersh; D D Miller
Journal:  J Am Coll Cardiol       Date:  1996-03-15       Impact factor: 24.094

10.  Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery.

Authors:  K A Eagle; C M Coley; J B Newell; D C Brewster; R C Darling; H W Strauss; T E Guiney; C A Boucher
Journal:  Ann Intern Med       Date:  1989-06-01       Impact factor: 25.391

View more
  1 in total

1.  Plasma N-terminal pro-B-type natriuretic peptide is predictive of perioperative cardiac events in patients undergoing vascular surgery.

Authors:  Ji Hyun Yang; Jin Ho Choi; Young-Wook Ki; Dong Ik Kim; Duk-Kyung Kim; Jeong Rang Park; Jae K Oh; Seung-Hyuk Choi
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.